Josh Cohen (L) and Justin Klee (Amylyx)

A pair of young biotech ex­ecs snag a mega-round for their late-stage ALS drug as the FDA sig­nals a more flex­i­ble ap­proach to an OK

Five years af­ter Justin Klee and Josh Co­hen got a lit­tle seed cash from the late Boston biotech leg­end Hen­ri Ter­meer to see if they could do some­thing se­ri­ous with a col­lege sci­ence project they had cooked up for ALS, the two young en­tre­pre­neurs have as­sem­bled an ex­ec­u­tive team and a syn­di­cate will­ing to put up a mega-round for the piv­otal test while set­ting the stage on com­mer­cial­iza­tion.

And while they’re al­ready fil­ing for an OK in Cana­da and Eu­rope this year, the co-CEOs at Amy­lyx have al­so en­gaged in talks to see if the FDA may prove open to a quick pitch now that Bio­gen’s Aduhelm has bro­ken through in Alzheimer’s with its frag­men­tary col­lec­tion of da­ta.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.